December 16, 2019 / 11:41 PM / 4 months ago

FDA approves expanded label for Pfizer, Astellas' prostate cancer Xtandi

Dec 16 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc’s Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

The new approval is for patients with metastatic castration-sensitive prostate cancer, while the drug was earlier approved for non metastatic and metastatic castration-resistant prostate cancer. (Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below